THERANEXUS: New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)

Lyon, France - Austin, Texas, United States - 5 January 2023 - 6.00 pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development

Related Keywords

United States ,Paris ,France General ,France ,Texas ,San Francisco ,California ,French ,Craig Benson ,Thierry Lambert ,Marie Sebille ,Florence Portejoie ,Martin Pierre Laurent ,National Organization For Rare Disorders ,Neuroscience Innovation Forum ,Twitter ,Atomic Energy Commission ,Batten Disease Foundation ,Sachs Associates ,Beyond Batten Disease Foundation ,Theranexu Chief Medical Officer Marie Sebille ,Annual Neuroscience Innovation Forum ,Biotech Showcase ,Healthcare Conference ,Unified Batten Disease Rating Scale ,French Alternative Energies ,Euronext Growth ,Rare Disorders ,Theranexus ,Advance ,Bbdf ,Thatten ,Program ,Juvenile ,Disease ,Ln3 ,